2024 Targeted Therapies for Lung Cancer (TTLC) - Abstracts & Posters-PP01.03 Porugari

PP01.03 Porugari - Poster

Pdf Summary

Small-cell lung cancer (SCLC) typically presents with a large hilar mass, mediastinal lymphadenopathy, and metastasis, but increased lung cancer screening has led to the incidental discovery of SCLC in biopsies of small lung nodules. A retrospective study on SCLC patients at Henry Ford Health System analyzed outcomes based on tumor size. Patients with tumors ≤ 2cm had better overall and progression-free survival compared to larger tumors. However, those with small tumors had similar outcomes to limited-stage patients. Diagnosis of extensive-stage disease, despite a small tumor size, was linked to poorer survival rates. The study found no significant association between brain metastasis at diagnosis and tumor size. The analysis also showed that extensive-stage disease was associated with worse overall survival and progression-free survival regardless of tumor size. The study's hypothesis that smaller tumors lead to better outcomes than larger ones was validated. The majority of patients had tumors ≤ 2cm, with limited-stage patients showing higher survival rates than those with extensive-stage disease. The research contributes to understanding the impact of tumor size on SCLC outcomes, emphasizing the importance of considering tumor size and stage in treatment planning for SCLC patients.

Keywords

Small-cell lung cancer

SCLC

Hilar mass

Mediastinal lymphadenopathy

Metastasis

Tumor size

Overall survival

Progression-free survival

Extensive-stage disease

Brain metastasis